Quoin evaluates QRX003 in Phase 2/3 trial for Netherton syndrome
QNRX•Phase 2/3 trial update
Quoin Pharmaceuticals highlighted positive interim results already released on Aug. 28 from its ongoing Phase 2/3 QRX003 trial in Netherton syndrome.
The update signals the study is progressing with encouraging early signs, supporting continued development toward a first approved treatment in the indication.
No future presentation date for additional trial results was disclosed.
